| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 13, 2006
Accepted on November 30, 2006
Huffington Center on Aging , Department of Molecular and Cellular Biology ; Division of Endocrinology, Department of Medicineand Michael E. DeBakey Houston Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX
* To whom correspondence should be addressed. E-mail: yuxiangs{at}bcm.tmc.edu.
In well-nourished humans, growth hormone (GH) and insulin-like growth factor (IGF-1) decline during aging and the responsiveness of GH axis to exogenous ghrelin is attenuated with age. Intriguingly, the GH/IGF-1 axis is rejuvenated by chronic treatment with the ghrelin mimetic, MK-0677, resulting in improvements in body composition, suggesting that frail elderly subjects might benefit from treatment with ghrelin and ghrelin mimetics. Mouse models are widely used to study the effects of ghrelin, but the impact of age on the ghrelin pathway is unclear. In this study, total and active ghrelin peptides were measured in plasma, and ghrelin mRNA was quantitated in brain tissue from different aged C57BL/6J mice. Surprisingly, plasma levels of ghrelin peptide slightly increased with age; ghrelin mRNA levels were similar in brains from mice aged 2, 6, 12 and 28 months, but higher in mice aged 18- and 24-months. The tissue distribution of Ghsr1a mRNA (ghrelin receptor) was also characterized and pituitary and brain exhibited the highest levels of expression. In the pituitary gland, the highest concentration of Ghsr1a mRNA was observed at age 1-2 months, it was lower at 6 months, and remained unchanged for up to 30-months of age. This result is consistent with the finding that GH release in response to exogenous ghrelin was not significantly different in mice aged 7-30 months. In the brain, Ghsr1a mRNA levels remained stable during aging. Hence, in C57BL/6J male mice, aging is not associated with changes in circulating ghrelin levels or changes in ghrelin receptor expression in the pituitary gland and brain.
This article has been cited by other articles:
 |
|
 |
|
  H. Ariyasu, H. Iwakura, G. Yamada, K. Nakao, K. Kangawa, and T. Akamizu Efficacy of Ghrelin as a Therapeutic Approach for Age-Related Physiological Changes Endocrinology, July 1, 2008; 149(7): 3722 - 3728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yukawa, D. S. Weigle, C. D. Davis, B. T. Marck, and T. Wolden-Hanson Peripheral ghrelin treatment stabilizes body weights of senescent male Brown Norway rats at baseline and after surgery Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1453 - R1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Garcia, J. P. Cata, P. M. Dougherty, and R. G. Smith Ghrelin Prevents Cisplatin-Induced Mechanical Hyperalgesia and Cachexia Endocrinology, February 1, 2008; 149(2): 455 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Granado, A. I. Martin, M. Lopez-Menduina, A. Lopez-Calderon, and M. A. Villanua GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E131 - E141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G.-S. Frutos, L. Cacicedo, C. Fernandez, D. Vicent, B. Velasco, H. Zapatero, and F. Sanchez-Franco Insights into a role of GH secretagogues in reversing the age-related decline in the GH/IGF-I axis Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1140 - E1152. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
